Aotech

Aotech is a French clinical-stage biotechnology company specializing in the development of Live Biotherapeutic Products (LBPs) for the treatment of inflammatory and metabolic diseases. A spin-off from INRAE and the University of Clermont Auvergne, the company leverages over a decade of research into the therapeutic potential of the human gut microbiome. Its lead candidate, AOT-001, is a single-strain LBP based on the commensal bacterium Bacteroides xylanisolvens, currently in Phase 2 clinical development for mild-to-moderate Ulcerative Colitis. Aotech's platform focuses on identifying and characterizing specific bacterial strains with potent immunomodulatory and metabolic properties to restore gut homeostasis. The company is supported by leading European venture capital firms and aims to pioneer a new class of oral microbiome-based therapies.